BioSpace News Archive

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the fourth quarter of 2022.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.

Vaxcyte, Inc. (Nasdaq: PCVX) announced today the closing of its previously announced underwritten public offering of 17,812,500 shares of common stock at a public offering price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $31.999 per underlying share.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Nuvalent, Inc. announced the initial data from the Phase 1 dose-escalation portion of its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors.

Octave announced the presentation of data from 13 abstracts presented at the European Committee for Treatment and Research in Multiple Sclerosis Conference 2022.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award.

RadNet, Inc. announced that it will host a conference call to discuss its third quarter 2022 financial results on Wednesday, November 9th, 2022 at 7:30 a.m. Pacific Time.

Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its third quarter of 2022 ended September 30, 2022, after the market closes on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.